Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects

Cardiovasc Res. 2009 Apr 1;82(1):100-6. doi: 10.1093/cvr/cvp005. Epub 2009 Jan 9.

Abstract

Aims: Atorvastatin blunts the response of cardiomyocytes to catecholamines by reducing isoprenylation of G gamma subunits. We examined whether atorvastatin exerts similar effects in vivo and protects the rat heart from harmful effects of catecholamines.

Methods and results: Rats were treated with atorvastatin (1 or 10 mg/kg x day) or H(2)O for 14 days per gavage. All three animal groups were subjected to restraint stress on day 10 and to infusions of isoprenaline (ISO; 1 mg/kg x day) or NaCl via minipumps for the last 4 days. Heart rate was measured by telemetry, left ventricular atrial natriuretic peptide (ANP) transcript levels by RT-PCR, and left atrial contractile function in organ baths. Heart rate was similar in all six study groups. In animals pre-treated with water, infusion of ISO induced an increase in heart-to-body weight ratio (HW/BW) by approximately 20%, an increase in ANP mRNA by approximately 350%, and a reduction in the inotropic effect of isoprenaline in left atrium by approximately 50%. In animals pre-treated with high-dose atorvastatin, the effects of ISO on HW/BW, ANP, and left atrial force were approximately 40, 50, and 40% smaller, respectively. Low dose atorvastatin had similar, albeit smaller effects. Atorvastatin treatment of NaCl-infused rats had only marginal effects. In cardiac homogenates from atorvastatin-treated rats (both NaCl- and ISO-infused), G gamma and G alpha(s) were partially translocated from the membrane to the cytosol.

Conclusion: In the rat heart, treatment with atorvastatin results in translocation of cardiac membrane G gamma and G alpha(s) to the cytosol. This mechanism might contribute to protecting the heart from harm induced by chronic isoprenaline infusion without affecting heart rate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / administration & dosage
  • Adrenergic beta-Agonists / toxicity*
  • Animals
  • Atorvastatin
  • Atrial Natriuretic Factor / genetics
  • Atrial Natriuretic Factor / metabolism
  • Cardiomegaly / chemically induced
  • Cardiomegaly / prevention & control
  • Cell Membrane / drug effects
  • Cell Membrane / metabolism
  • Circadian Rhythm
  • Cytosol / metabolism
  • GTP-Binding Protein alpha Subunits, Gs / metabolism
  • GTP-Binding Protein gamma Subunits / metabolism
  • Heart / drug effects*
  • Heart / physiopathology
  • Heart Rate / drug effects*
  • Heptanoic Acids / pharmacology*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Infusion Pumps, Implantable
  • Isoproterenol / administration & dosage
  • Isoproterenol / toxicity*
  • Male
  • Myocardial Contraction / drug effects*
  • Myocardium / metabolism
  • Protein Transport
  • Pyrroles / pharmacology*
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Wistar

Substances

  • Adrenergic beta-Agonists
  • GTP-Binding Protein gamma Subunits
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyrroles
  • RNA, Messenger
  • Atrial Natriuretic Factor
  • Atorvastatin
  • GTP-Binding Protein alpha Subunits, Gs
  • Isoproterenol